Antibodies for bioanalysis and drug monitoring of certolizumab pegol and biosimilars

Develop an ADA assay for Fab fragment drug certolizumab pegol (Cimzia) using ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to certolizumab pegol
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Certolizumab Pegol.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Certolizumab pegol
Inhibitory

Type 1

HCA324

AbD34136ia

Human IgG1

3.0

ADA control

Order HCA324

HCA325

AbD34201ia

Human IgG1

1.0

ADA control

Order HCA325

HCA326

AbD34202ia

Human IgG1

2.0

ADA control

Order HCA326

* Affinity measured in the monovalent Fab format 


Anti-Certolizmab Pegol Inhibitory Antibodies (Type 1)

Type 1 anti-certolizumab pegol antibodies inhibit the binding of the drug certolizumab pegol to its target, tumor necrosis factor alpha (TNFα). They are available with three different affinities, and are suitable as a surrogate positive control or reference standard for an anti-drug antibody (ADA) assay.


ELISA Protocol to Get You Started

ADA Bridging ELISA


Fig. 1. Certolizumab pegol ADA bridging ELISA using antibody HCA324, 325 or 326.

Fig. 1. Certolizumab pegol ADA bridging ELISA using antibody HCA324, HCA325 or HCA326.

Schematic image of PK Bridging ELISA. Capture antibody, Fab format (purple), fusion protein drug (gold-green), detection antibody, Ig format (blue), labeled with HRP

Schematic image of ADA bridging assay. Monovalent Fab fragment drug as capture and detection reagent labeled with HRP (gold), fully human anti-drug antibody, Ig format (blue).



Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.